AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1-13. (cancelled)

14. (currently amended) A pharmaceutical composition comprising an antibody to C3b(i) conjugated to a therapeutic agent ~~or an antibody to C3b(i) covalently linked to a second molecule~~, in an amount effective to inhibit or prevent cancer in a subject.

15. (cancelled)

16. (currently amended) The pharmaceutical composition of Claim 14 ~~or 15~~ in which the antibody is specific for C3b(i) covalently linked to IgM on cancer cells.

17. (currently amended) The pharmaceutical composition of Claim 14 ~~or 15~~ in which the antibody is specific for C3b(i) covalently linked to glycoproteins or glycolipids on cancer cells.

18. (currently amended) ~~A~~ The pharmaceutical composition of Claim 14, wherein the antibody is ~~comprising~~ a bispecific antibody which is specific for C3b(i) and an effector cell receptor or antigen~~, in an amount effective to inhibit or present cancer in a subject~~.

19-40. (cancelled)

41. (original) The pharmaceutical composition of Claim 14 in which the antibody is purified.

42. (original) The pharmaceutical composition of Claim 14 or 41 further comprising a pharmaceutically acceptable carrier.

43. (currently amended) A kit comprising, in one or more containers, an antibody to C3b(i) conjugated to a therapeutic agent ~~or an antibody to C3b(i) covalently linked to a second molecule~~.

44. (original) The kit of Claim 43 further comprising IgM antibody.

45. (original) The kit of Claim 43 or 44 further comprising one or more complement components.

46-47. (cancelled)

48. (new) The pharmaceutical composition of Claim 14, wherein the antibody is a monoclonal antibody.

49. (new) The pharmaceutical composition of Claim 14, wherein the antibody is a humanized antibody.

50. (new) The pharmaceutical composition of Claim 14, wherein the therapeutic agent is a radioactive agent.

51. (new) The pharmaceutical composition of Claim 14, wherein the therapeutic agent is a cytotoxin.

52. (new) The pharmaceutical composition of Claim 14, wherein the therapeutic agent is selected from the group consisting of paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin.

53. (new) The pharmaceutical composition of Claim 14, wherein the therapeutic agent is cobra venom factor.

54. (new) The pharmaceutical composition of Claim 14, wherein the therapeutic agent is abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin.

55. (new) The pharmaceutical composition of any one of Claim 16-18 or 48-54, wherein the antibody is purified.